Healios K.K (TYO:4593) said it made progress on its application for conditional approval of its MultiStem ARDS treatment in Japan after agreeing with regulators on manufacturing details, according to a Thursday filing on the Tokyo Stock Exchange.
Clinical aspects of the application will be discussed with regulators in mid-January 2025.
Price (JPY): $167.00, Change: $+3.0, Percent Change: +1.83%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。